Versatility of OnabotulinumtoxinA in Aesthetic Medicine

Mitchell F Brin,John Maltman,Mary Ann Chapman,Sara Sangha
DOI: https://doi.org/10.1097/DSS.0000000000004348
2024-09-01
Abstract:Background: OnabotulinumtoxinA is an injectable product that was introduced into medicine in the 1970s and has been the subject of thousands of clinical and nonclinical publications. Objective: To review the data related to the versatility of onabotulinumtoxinA in medical aesthetics. Methods: PubMed was searched to identify literature evaluating the effects of onabotulinumtoxinA, with preference given to randomized, placebo-controlled trials and safety meta-analyses. Results: OnabotulinumtoxinA is effective and safe across multiple facial indications, racial and ethnic groups, age groups, genders, and facial line severities. Patient-reported outcomes have been prioritized in aesthetic clinical trials and indicate high patient satisfaction and appearance-related psychological outcomes. Integrated safety meta-analysis and immunogenicity analyses have documented acceptable adverse event rates and low immunogenicity of onabotulinumtoxinA. Conclusion: OnabotulinumtoxinA is a versatile aesthetic product supported by a strong literature base and positive physician and patient-reported outcomes that reflect a meaningful impact on patient's quality of life.
What problem does this paper attempt to address?